Emergent Biosolutions (NYSE: EBS) — Perfil da empresa, notícias e dados financeiros
Emergent Biosolutions develops biopharmaceuticals for public health threats, focusing on infectious diseases and opioid overdoses.
Emergent Biosolutions
Emergent Biosolutions (NYSE:EBS) is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medical countermeasures for public health threats. Through its multi-faceted approach, Emergent targets a wide range of pressing health concerns, from infectious diseases to opioid overdoses. With a portfolio that includes vaccines, therapeutics, and devices, Emergent aims to protect and enhance life by providing solutions that address some of the world's most pressing public health challenges. The company is also deeply involved in various projects aimed at combating emerging health threats, demonstrating its commitment to innovation and public service. By collaborating with governments, healthcare providers, and other key stakeholders, Emergent strives to fulfill its objective of making a significant impact on global health security.
Resumo
Operações
Produtos e/ou serviços de Emergent Biosolutions
- Narcan Nasal Spray for opioid overdose reversal is a life-saving medication that rapidly counters the effects of opioid drugs.
- BioThrax (Anthrax Vaccine Adsorbed) is the only FDA-approved vaccine for pre-exposure prophylaxis of anthrax disease.
- Raxibacumab, an antibody therapeutic, is used to treat inhalational anthrax, providing an alternative when traditional therapies are not suitable.
- Vivotif, an oral typhoid vaccine, offers protection against typhoid fever, a common and potentially severe bacterial infection.
- ACAM2000 is a vaccine for the prevention of smallpox, a critical component in biodefense against potential bioterrorism.
- BAT (Botulism Antitoxin Heptavalent) is a treatment for botulinum toxin types A through G, essential for addressing botulism poisoning.
equipe executiva do Emergent Biosolutions
- Joseph C. Papa Jr.CEO, President & Director
- Richard S. LindahlExecutive VP & CFO
- Coleen GlessnerExecutive Vice President of Quality, Ethics & Compliance
- Paul A. WilliamsSenior Vice President of Products Business
- Jessica PerlSenior VP, Corporate Secretary & General Counsel
- Assal HellmerVice President of Communications
- Michelle PepinSenior VP & Chief Human Resource Officer
- Stephanie DuatschekExecutive VP & Chief Growth Officer
- William HartzelSenior Vice President of Manufacturing & Bioservices
- Frank VargoVP & Treasurer
Últimas notícias sobre a Emergent Biosolutions
Histórico de dividendos
Dividendos por ação pagos pela Emergent Biosolutions, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2016 | — | — | — | $1.8550 |
Principais indicadores financeiros
Resultados divulgados pela Emergent Biosolutions, em USD.
- Cap. de mercado
- 342 mi
- Receita (TTM)
- 770,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.4
- Dividend yield
- —
- Margem de lucro
- -23.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 742,9 mi | 110,2 mi | 52,6 mi | |
| 1 bi | -108,7 mi | -190,6 mi | |
| 1 bi | -726,4 mi | -760,5 mi | |
| 1,1 bi | -170 mi | -211,6 mi |